CA2564742A1 — Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
Assigned to Glaxo Group Ltd · Expires 2005-11-10 · 21y expired
What this patent protects
Compounds of formula I (see formula I) and pharmaceutical compositions comprising same are disclosed. The compounds of the invention are muscarinic acethylcholine receptor antogonists which can be used in the treatment of a muscarinic acetylcholine receptor mediated disease.
USPTO Abstract
Compounds of formula I (see formula I) and pharmaceutical compositions comprising same are disclosed. The compounds of the invention are muscarinic acethylcholine receptor antogonists which can be used in the treatment of a muscarinic acetylcholine receptor mediated disease.
Drugs covered by this patent
- Arnuity Ellipta (FLUTICASONE FUROATE) · Haleon Us Holdings
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.